Walvax Biotechnology (300142) Fundamentals 2026 — P/E 75.5x, Revenue Analysis | SniperIQ
Walvax Biotechnology (300142) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥21.6B, trading at ¥13.49 on the SHZ. This SniperIQ fundamentals page covers Walvax Biotechnology's valuation (P/E 75.5x, P/B 2.9x), profitability (net margin 11.9%), revenue (¥2.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Walvax Biotechnology's market cap?
Walvax Biotechnology (300142) has a market capitalization of approximately ¥21.6B, trading at ¥13.49 on the SHZ. Market cap moves with the live share price.
What is Walvax Biotechnology's P/E ratio?
Walvax Biotechnology's trailing twelve-month P/E ratio is 75.5x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Walvax Biotechnology?
Walvax Biotechnology runs a net profit margin of 11.9%, a gross margin of 68.3%, and an operating margin of 9.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Walvax Biotechnology generate?
Walvax Biotechnology reported revenue of ¥2.4B for fiscal year 2025, with net income of ¥178M and earnings per share (EPS) of 0.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Walvax Biotechnology pay a dividend?
Walvax Biotechnology offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Walvax Biotechnology financially healthy?
Walvax Biotechnology carries a debt-to-equity ratio of 0.19x and a current ratio of 2.16x, with a market beta of 0.38. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Walvax Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Walvax Biotechnology (300142) the key facts are: market cap ¥21.6B, P/E 75.5x, revenue ¥2.4B, 52-week range 10.88-16.23. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Walvax Biotechnology's full fundamentals live
Get Walvax Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.